AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Gen Z protests swept 34 German cities on Saturday (31 October) over education, living costs and military service proposals. Violence erupted in Fra...
Iran designated Britain's Royal Navy and Royal Air Force as terrorist organisations on Sunday, (1 November), and classified the country's f...
Since 2021, only 9 per cent of $8 billion in humanitarian aid for Afghanistan can be traced beyond initial recipients in public re...
The U.S. has approved the sale of 500 Patriot PAC-3 missiles to Ukraine in a deal worth an estimated $2.1 billion, but Kyiv could face years of delays before receiving the weapons it urgently needs to defend against intensifying Russian attacks.
Iranian Supreme Leader Ayatollah Khamenei has ordered Iran's armed forces to respond to any threat immediately and without geographical limits in statements posted to social media platforms on Saturday (31 October).
Demonstrators carrying Iranian flags and placards supporting the hijab gathered outside the Azerbaijani Embassy in London.
A Chinese-made AI chip has matched Nvidia’s H200 in tests conducted by its developer, marking a potential breakthrough in China’s efforts to reduce its dependence on foreign technology.
A hacking group linked to North Korea is widely believed to be behind the theft of $6.3 billion from cryptocurrency giant Binance, a cyberattack that experts describe as the largest cryptocurrency heist on record.
Dengue fever has killed more people in Bangladesh this year than in the whole of 2025, with October the deadliest month so far, data from Bangladesh's Health Ministry shows.
Visitors to Armenia could face temperature screening after a lab worker died from suspected Pneumonic plague in Russia, Yerevan’s Health Minister Anahit Avanesyan told lawmakers on Wednesday, Armenian state news agency Armenpress reported.
Health advice now reaches people through social media, fitness apps, wearable technology and AI. From detoxes and protein-focused diets to skincare and fitness trends, online wellness content is shaping everyday health choices while raising concerns about misinformation and potential risks.
Global cholera deaths reached their highest annual level in more than 20 years in 2025, despite a decline in reported cases, according to the World Health Organization (WHO).
Chinese researchers have developed the world’s smallest CT scanner, a portable device designed to produce images of tiny fossils and archaeological relics.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment